Clinical trial design in brain metastasis: approaches for a unique patient population (Q48806386)

15 February 2018

title

Clinical trial design in brain metastasis: approaches for a unique patient population (English)

1 reference

15 February 2018

1 reference

David M Peereboom

1

1 reference

15 February 2018

publication date

1 February 2012

1 reference

15 February 2018

published in

Current Oncology Reports

1 reference

15 February 2018

volume

14

1 reference

15 February 2018

issue

1

1 reference

15 February 2018

page(s)

91-96

1 reference

15 February 2018

Chemotherapy induces regression of brain metastases in breast carcinoma

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

Response of brain metastases from breast cancer to systemic chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

Brain metastases as preventive and therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

Sagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

Chemotherapy delivery issues in central nervous system malignancy: a reality check.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

Brain metastasis in melanoma: clinical activity of CTLA-4 antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

Pathway analysis of glioblastoma tissue after preoperative treatment with the EGFR tyrosine kinase inhibitor gefitinib--a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

Clinical trial end points for high-grade glioma: the evolving landscape.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

Dose-dense temozolomide regimen for the treatment of brain metastases from melanoma, breast cancer, or lung cancer not amenable to surgery or radiosurgery: a multicenter phase II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

Phase I clinical trial outcomes in 93 patients with brain metastases: the MD anderson cancer center experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

It is time to include patients with brain tumors in phase I trials in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

The design of phase II clinical trials testing cancer therapeutics: consensus recommendations from the clinical trial design task force of the national cancer institute investigational drug steering committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

21 January 2018

Bayesian clinical trials

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0204-X

A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases

21 January 2018

1 reference

12 December 2020

Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study

1 reference

12 December 2020

HER2 status in a population-derived breast cancer cohort: discordances during tumor progression

1 reference

12 December 2020

Complete regression of a previously untreated melanoma brain metastasis with ipilimumab

1 reference

12 December 2020

Adaptive clinical trials: the promise and the caution

1 reference

12 December 2020

Combination therapy with platinum and etoposide of brain metastases from breast carcinoma

1 reference

12 December 2020

The Italian Network for Tumor Biotherapy (NIBIT). Sharing visions, goals and efforts at European level

1 reference

12 December 2020

Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy--a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group

1 reference

12 December 2020

Phase II trial of radiosurgery for one to three newly diagnosed brain metastases from renal cell carcinoma, melanoma, and sarcoma: an Eastern Cooperative Oncology Group study (E 6397)

1 reference

12 December 2020

Medical oncology: Patients with brain metastases in early-phase trials

1 reference

12 December 2020

Combination chemotherapy of cisplatin, ifosfamide, and irinotecan with rhG-CSF support in patients with brain metastases from non-small cell lung cancer

1 reference

12 December 2020

Endothelial apoptosis initiates acute blood-brain barrier disruption after ionizing radiation

1 reference

12 December 2020

Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study

1 reference

12 December 2020

BATTLE to personalize lung cancer treatment. Novel clinical trial design and tissue gathering procedures drive biomarker discovery

1 reference

12 December 2020

Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Français de Pneumo-Cancérologie (GFPC) Protocol

1 reference

12 December 2020

10.1007/S11912-011-0204-X

Identifiers

DOI

1 reference

15 February 2018

1 reference

15 February 2018